|
⚲
|
| Keyboard |
| Sarissa Capital Management LP
✚
|
|
|---|---|
| CRD # | 167244 |
| SEC # | 801-77926 |
| CIK # | 0001577524 |
| AUM | 298.3 M (2026-03-31) |
| Employees | 4 (75% Investors, 0% Brokers) |
| Phone | 203-302-2330 |
| Address | 500 West Putnam Avenue Greenwich, CT 06830 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] |
| Total AUM ($M) |
|---|
| Sector | Form 13F Holdings | Value ($M) | |
|---|---|---|---|
| Theravance Inc | 49.7 | ||
| Ironwood Pharmaceuticals Inc | 32.3 | ||
| Amarin Corp PLC UK | 24.2 | ||
| Neurocrine Biosciences Inc | 15.4 | ||
| Cytokinetics Inc | 15.1 | ||
| Lantheus Holdings Inc | 12.7 | ||
| Biohaven Ltd | 4.8 | ||
| Regeneron Pharmaceuticals Inc | 3.2 | ||
| Vor Biopharma Inc | 0.5 | ||
| Holdings by Sector ($M) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| HF | ISP Fund LP | 2021-03-31 | 79.5 M | |
| HF | Sarissa Capital Master Fund II LP | [2021-03-31] | 9.0 M | 9.8 M |
| Filed 2024-05-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sarissa Capital Athena Fund Ltd | 2020-03-30 | 59.4 M | |
| HF | Sarissa Capital Hawkeye Fund LP | 2020-03-30 | 22.2 M | |
| HF | Sarissa Capital Catapult Fund LLC | [2018-03-29] | 132.3 M | 130.7 M |
| Filed 2025-11-12 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sarissa Capital Domestic Fund LP | [2013-04-02] | 351.7 M | 321.5 M |
| Filed 2025-07-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | Sarissa Capital Offshore Master Fund LP | [2013-04-02] | 65.9 M | |
| Filed 2025-07-16 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 6 | 298.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 6 | 298.3 |
| By Discretionary | ||
| Discretionary | 6 | 298.3 |
| Non-Discretionary | 0 | 0.0 |
| Total | 6 | 298.3 |
| By Non-United States Persons | ||
| Non-United States Persons | 39.6 | |
| United States Persons | 258.8 | |
| Total | 6 | 298.3 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Geoff Ruddick | Director | 256 | 66 | |
| Jonathan Roney | Director | 99 | 18 | |
| Alexander Denner | Director, Executive Officer | 6 | 2 | |
| Sarissa Capital Fund GP LP | Director | 1 | 1 | |
| Mark Dipaolo | Executive Officer | 1 | 1 | |
| Patrice Bonfiglio | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001577524] | |
| 3 | [0001577524] | |
| 4 | [0001577524] | |
| SC 13D | [0001577524] | |
| SC 13G | [0001577524] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.6B |
| Serves | Institutional |
| Fund Types | Hedge Fund |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-12-15 | Grant | 4,178 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-06-13 | Grant | 24,193 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-06-10 | Grant | 45,000 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2025-04-02 | Grant | 10,416 | $0.00 | |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2025-03-06 | Sell | 1,196,746 | $17.52 | 20,966,990 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2025-03-05 | Sell | 270,374 | $17.63 | 4,766,694 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2025-03-04 | Sell | 151,175 | $17.63 | 2,665,215 |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-12-16 | Grant | 4,249 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-09-16 | Grant | 3,282 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-06-18 | Grant | 24,311 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-06-15 | Grant | 2,572 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2024-03-15 | Grant | 1,662 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-12-15 | Grant | 1,347 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-09-15 | Grant | 1,798 | $0.00 | |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-06-20 | Grant | 22,350 | $0.00 | |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-06-15 | Buy | 62,000 | $13.13 | 814,060 |
|
Ironwood Pharmaceuticals Inc IRWD
Class A Common Stock
|
2023-06-15 | Grant | 1,359 | $0.00 | |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-06-06 | Buy | 8,000 | $13.05 | 104,400 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-06-05 | Buy | 7,000 | $13.04 | 91,280 |
|
Theravance Inc INVA
Common Stock, par value $0.01 per share
|
2023-05-30 | Buy | 120,000 | $13.01 | 1,561,200 |
| showing 20 of 57 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Panoramic Capital LLC
✚
|
CA | 299.6 M |
|
Greenhaven Road Investment Management LP
✚
|
CT | 299.5 M |
|
Polpo Capital Management LLC
✚
|
299.5 M | |
|
MQS Management LLC
✚
|
NY | 299.4 M |
|
Osmosis Investment Management US LLC
✚
|
298.9 M | |
|
GS Gamma Advisors LLC
✚
|
NY | 298.6 M |
|
Mercator Management USA LP
✚
|
NJ | 297.6 M |
|
Ananym Capital Management LP
✚
|
NY | 297.6 M |
|
High Trail Capital LP
✚
|
NJ | 296.9 M |
|
ADW Capital Management LLC
✚
|
296.8 M |